By Michael Dabaie

 

Immutep Ltd. said interim data was positive from its ongoing Phase II TACTI-002 study.

ADRs were down 1% to $3.00 premarket.

The data relates to use of the company's lead product candidate eftilagimod alpha, as part of a combination treatment with pembrolizumab. The activation of antigen-presenting cells and subsequent T cell recruitment with efti may lead to stronger anti-tumour responses than observed with pembrolizumab alone, the company said.

The company said there were responses in 47% of first line non-small cell lung cancer patients. Immutep said usually only 20% of patients respond to pembrolizumab monotherapy, if not preselected for high PD-L1 expression.

The initial overall response rate was 33% of second line head and neck squamous cell carcinoma patients.

The company said 59% of the NSCLC patients are still under therapy with 7-plus months, and median progression-free survival hasn't yet been reached.

Immutep said TACTI-002 is being conducted in collaboration with Merck & Co. It is evaluating the combination of efti with Merck's Keytruda in up to 109 patients.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

February 19, 2020 08:38 ET (13:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more Merck Charts.